Abstract
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been recently recognized as one of foundational therapies in patients with cardiovascular diseases (CVDs), including heart failure (HF), beyond the use in the diabetes care setting. In particular, SGLT2 inhibitors reduced the risk of HF-related events and cardiovascular death in a broad clinical manifestation of HF, including chronic and even acute HF, regardless of left ventricular ejection fraction. On the other hand, whether treatment with SGLT2 inhibitor can reduce the risk of atherosclerotic CVDs is still uncertain. Moreover, its effects on vascular function and atherosclerosis remain also to be inconclusive. In this talk, we would like to review the effects of SGLT2 inhibition on vascular function and atherosclerosis, based on the recent insights observed in the pragmatic randomized clinical trials, and discuss its role in the cardiovascular care setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
